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brain  injury  as  well  as  life-threatening  cerebral
edema  in  severe  cases.  Previous  studies  on  the
mechanisms  of  HH-induced  brain  injury  have  been
conducted  primarily  using  non-primate  animal
models  that  are  genetically  distant  to  humans,  thus
hindering  the  development  of  disease  treatment.
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fascicularis) exposed to acute HH developed human-
like  HH  syndrome  involving  severe  brain  injury  and
abnormal  behavior.  Transcriptome  profiling  of  white
blood  cells  and  brain  tissue  from monkeys  exposed
to increasing altitude revealed the central role of the
HIF-1  and  other  novel  signaling  pathways,  such  as
the  vitamin  D  receptor  (VDR)  signaling  pathway,  in
co-regulating  HH-induced  inflammation  processes.
We  also  observed  profound  transcriptomic
alterations  in  brains  after  exposure  to  acute  HH,
including  the  activation  of  angiogenesis  and
impairment of aerobic respiration and protein folding
processes,  which  likely  underlie  the  pathological
effects  of  HH-induced  brain  injury.  Administration  of
progesterone  (PROG)  and  steroid  neuroprotectant
5α-androst-3β,5,6β-triol  (TRIOL)  significantly
attenuated  brain  injuries  and  rescued  the
transcriptomic  changes  induced  by  acute  HH.
Functional  investigation  of  the  affected  genes
suggested  that  these  two  neuroprotectants  protect
the brain by targeting different pathways, with PROG
enhancing  erythropoiesis  and  TRIOL  suppressing
glutamate-induced  excitotoxicity.  Thus,  this  study
advances  our  understanding  of  the  pathology
induced  by  acute  HH  and  provides  potential
compounds  for  the  development  of  neuroprotectant
drugs for therapeutic treatment.
Keywords:   Acute hypobaric hypoxia;   Cynomolgus
monkeys;    Brain  injury;    Neuroprotectant;    Gene
regulatory networks
INTRODUCTION
High  altitude,  which  represents  one  of  the  most  extreme
environments  on  Earth,  creates  hypobaric  hypoxia  (HH)
conditions  to  which  only  a  small  proportion  of  people  can
adapt. As the brain is the most hypoxia-intolerant organ, most
people  who  ascend  too  rapidly  to  high  altitudes  cannot
acclimatize to the HH environment and frequently suffer  from
a range of symptoms caused by acute hypoxia (Wilson et al.,
2009).  In  severe  cases,  patients  can  develop  serious  high-
altitude  cerebral  edema (HACE).  With  over  35  million  people
around the world traveling to high-altitude regions annually for
tourism,  sport,  or  work  (Martin  &  Windsor,  2008),  brain
damage  caused  by  HH  has  become  a  health  hazard  for
lowland  people  who  move  to  high  altitudes.  So  far,  the  main
mechanisms  underlying  brain  damage  include  metabolic
disturbance  of  neural  cells,  increased  permeability  of  brain





are  proposed  to  treat  or  even  prevent  HH-induced  brain
damage  and  edema  based  on  increased  oxygen-carrying
capacity  or  anti-inflammatory  effects  (Imray  et  al.,  2010).
However, their efficacy is still controversial and numerous side
effects  have  been  reported  in  relation  to  their  clinical  use
(Imray et al., 2010; Rabinstein, 2006). Progesterone (PROG),
a  well-known  endogenous  neuroprotective  sex  hormone,  is
reported  to  be  associated  with  acute  HH  acclimatization
(Stein, 2008). In addition, serum levels of PROG are found to
increase in men who travel to high-altitude areas (Basu et al.,
1997),  suggesting  the  possibility  that  PROG  may  ameliorate
HH-induced  brain  damage.  Furthermore,  as  first  reported  by
our  group  (Chen  et  al.,  2013a),  5α-androst-3β,5,6β-triol
(TRIOL)  is  a  novel  neuroprotectant  and  analogue  of  the








conditions  and  exhaustive  exercise  are  necessary  to  induce
HACE-like symptoms in rats (Guo et al., 2013), and very rapid
ascent  speed (velocity  of  50  m/s  within  5  min  to  6  000 m)  is
required to induce HACE-like symptoms in mice (Huang et al.,
2015).  In  addition,  the  potential  drug  targets  in  rodents  may
differ  from  those  in  humans  due  to  the  large  genetic
differences  between  rodents  and  primates  after  ~96  million
years  of  evolutionary  divergence  (Nei  et  al.,  2001).  In
particular,  the  central  nervous  system  (CNS)  of  primates  is
much more complex than that  of  rodents (Lissa et  al.,  2013).
Thus, given the limitations of rodent models, the establishment
of non-human primate models for HH study is urgently needed
and  should  provide  valuable  insights  into  the  molecular
cascades  and  gene  regulatory  networks  underlying  HH-
induced  brain  diseases  and  further  our  understanding  of  the




possible  effects  of  PROG  and  TRIOL  on  HH-induced  brain
damage  in  vivo.  Specifically,  we  established  a  non-human
primate  model  of  HH-induced  brain  damage  and  profiled  the
transcriptomes  of  white  blood  cells  (WBCs)  and  brain  tissue
from  cynomolgus  monkeys  before  and  after  acute  HH
exposure (i.e.,  increasing altitude).  Extensive gene regulatory
analyses  revealed  a  dynamic  change  in  the  WBC
transcriptome response to HH as well  as the gene regulatory
network  of  newly  identified  transcriptomic  hub  genes.
Moreover,  the  application  of  the  two  neuroprotectants
effectively  protected  the  brains  of  cynomolgus  monkeys  from
HH-induced  injury.  Finally,  PROG  and  TRIOL  exerted  their
effects  via  different  pathways,  the  former  through





All  experiments  were  conducted  in  accordance  with  the
Chinese Laws for the Protection of Animals. The experimental
protocols  were  approved  by  the  Ethics  Committee  of
Zhongshan  School  of  Medicine,  Sun  Yat-Sen  University
according  to  the  ARRIVE  (Animal  Research:  Reporting  of  In
Vivo  Experiments)  guidelines  (Kilkenny  et  al.,  2010).  All
animal-based procedures were performed in  strict  adherence




6.8 –7.5  kg)  were  obtained  from  Gaoyao  Kangda  Laboratory
Animals  Science  &  Technology  Co.,  Ltd,  Zhaoqing,
Guangdong Province, China. The animals were transported to
the  Third  Military  Medical  University,  Chongqing,  China.
Monkeys  were  singly  housed  in  cages  in  a  controlled
environment at a temperature of 25±1 °C, relative humidity of
60%,  and  circadian  12  h  light/dark  cycle  and  were  fed
routinely.
For  experimentation,  monkeys  were  randomly  divided  into
four  groups,  each  containing  six  individuals.  The  first  group





After  48 h  at  a  simulated  altitude  of  7 500 m,  the  HH
monkeys  were  sacrificed.  The  NN  monkeys  were  also
sacrificed after 3 d in the NN environment. All  monkeys were
euthanized  by  bloodletting  from the  carotid  under  anesthesia
using  a  mixture  of  injectable  ketamine  hydrochloride
(0.06 mg/kg) and xylazine hydrochloride (0.02 mg/kg).
Pharmacological treatments
Intravenous  (10  mg/mL)  and  extended-release  intramuscular
injections (50 mg/mL) of TRIOL were provided by Guangzhou
Cellprotek  Pharmaceutical  Company  Co.,  Ltd.  (China).  The
TRIOL (Batch No. 101124) was dissolved in vehicle containing
0.9%  sodium  chloride  and  20%  hydroxypropyl-β-cyclodextrin
(HP-β-CD) for intravenous injection, and in vehicle containing
12%  glycerin,  20%  HP-β-CD,  and  0.19%  CMC-Na  for
extended-release  intramuscular  injection.  Injectable
progesterone  (20 mg/mL)  was  purchased  from  Zhejiang
Xianju  Pharmaceutical  Co.,  Ltd.  (China),  with  a  CFDA
ratification No. of Guo Yao Zhun Zi-H33020828. The HP-β-CD
(Batch No. 100309) was purchased from Xi'an Deli Biology &
Chemical  Industry  Co.,  Ltd.  (China).  Injectable  ketamine
hydrochloride  (150 mg/mL)  was  purchased  from  Shenyang
Veterinary  Drugs  Co.,  Ltd.  (China)  with  an  approval  No.  of
(2011)060022668 by the Ministry of Agriculture of the People's
Republic  of  China  (PRC).  Injectable  xylazine  hydrochloride
(100 mg/mL)  was  purchased  from  Dunhua  Shengda
Veterinary  Drugs  Co.,  Ltd.  (China)  with  an  approval  No.  of
(2010)070031581 by the Ministry of Agriculture of the PRC.
Acute  hypobaric  hypoxia  and  neuroprotective  steroid
agent treatments
For  HH  treatment,  the  simulated  altitude  in  the  hypobaric
chamber was increased from 320 m to 6 000 m at a velocity of
3 m/s,  and  from  6 000 m  to  7 500 m  at  a  velocity  of  2 m/s.
Altitude  simulation  was  started  at  320 m  (stage  A),  then
suspended  at  3 000 m  (stage  B),  4  500 m  (stage  C),  and
6 000 m  (stage  D)  for 50 min each,  and  finally  maintained  at
7 500 m  for  an  initial  24 h  (stage  E)  and  then  another  24 h
(stage  F)  for  a  total  of  48 h.  At  every  stage,  monkeys  were
maintained  under  HH  conditions  for  30 min  at  the
corresponding  altitudes,  and  were  then  subjected  to  blood
sample  collection  and  drug  administration  within  20 min.
Because of safety concerns for the experimenters, the altitude
was  decreased  from 7 500 m to 6 000 m  for  blood  collection
and drug administration at stage E within 30 min. Throughout
the  HH  experimental  exposure,  the  temperature,  relative
humidity, and air-flow velocity of the chamber were maintained
at 22 °C, 60%, and 5 L/min, respectively.
For  the  HH+PROG  group,  animals  were  intramuscularly
injected  with  15  mg/kg  of  PROG  three  times,  first  at  12  h
before  HH  treatment,  then  during  stages  D  and  E.  For  the
HH+  TRIOL  group,  animals  were  intravenously  injected  with
10 mg/kg of TRIOL 5 min before HH treatment, and at stages
B, C, D, and E. Owing to TRIOL's short half-life (t1/2) of 0.5 h,
the  extended-release  intramuscular  injection  of  TRIOL  (30
mg/kg) was also administered at stages D and E.
Assessment of skeletal muscle coordination behavior
Behavioral  assessment  was  performed  by  trained
experimenters  blind  to  group  information.  Monkey  behavior
was  monitored  2 h  after  arrival  at  the  simulated  altitude  of
7 500 m. We observed their activities over the next 30 min and
employed a modified scale method to assess skeletal muscle
coordination,  with  higher  scores  indicating  more  severely
impaired  behavioral  states.  The  scoring  system  for  monkey
behavior  assessment  is  presented  in  Supplementary  Table
S1.
Measurement of brain water content
Left  brain  hemispheres  were  used  to  measure  brain  water
content with a precision electronic scale (Sartorius, BSA224S,




(dry  weight).  The  percentage  of  brain  water  content  was
calculated  as:  water  content  (%)=(wet  weight-dry  weight)/wet
weight×100%.
Transmission electron microscopy (TEM)
The frontal cortices of brains were divided into 1 mm×1 mm×
1  mm  pieces  and  fixed  in  2.5%  glutaraldehyde  overnight  at
4 °C.  The  fixed  brain  tissues  were  dehydrated  through  an
ethanol series, embedded in epoxy resin, and cut into 60 nm
ultrathin  sections  with  a  Leica  EM  UC6  Ultramicrocut
(Germany).  The sections  were  mounted  on  copper  grids  and
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then  stained  in  uranyl  acetate  and  citric  acid.  Images  were
captured  using  a  transmission  electron  microscope  (Tecnai




immediately  after  removal  and  then  fixed  in  4%
paraformaldehyde.  All  samples  were  dehydrated  in  an
increasing series of ethanol, cleared in xylene, and embedded
in paraffin. Brain sections of 5 μm-thickness were cut using a
rotary  microtome  (Shandon  Finesse  325,  Thermofisher
Scientific,  USA)  and  then  deparaffinized  with  xylene  and
hydrated,  followed  by  Nissl  staining  (0.5%  cresyl  violet)  for
histopathological  assessment  of  neuronal  injury.  For  Nissl
staining, injured neurons were characterized by dark staining,
condensed nuclei, shrunken cell bodies, or weak staining with





(RBCs)  were  lysed  by  gently  mixing  the  blood  sample  with
Red Cell  Lysis  Buffer  (1:3),  followed by  incubation  on  ice  for
5 min. The precipitate was then harvested by centrifugation at
2 500 g for 5 min at 4 °C. The WBC samples were ready for
total  RNA  extraction  after  the  isolation  procedure  was
repeated three times.
RNA extraction, library construction, and sequencing
Total RNA was extracted and purified from WBCs and frontal
cortices  using  Trizol  reagent  (Invitrogen,  15596,  USA)
according  to  the  manufacturer's  standard  protocols.  RNA
quality  and  concentration  were  assessed  using  an  Agilent
Bioanalyzer  2100  and  RNA  6000  Nano  Kit  (Agilent
Technologies, USA). One of the TRIOL-treated monkeys was
removed from RNA-seq analysis because the blood and brain
RNA samples  were  poorly  preserved  due  to  depletion  of  dry
ice  during  delivery  to  the  sequencing  company.  One  of  the
stage-A  WBC  samples  from  the  HH+PROG  group  was  also
removed due to severe degradation of RNA.
For  library  construction,  oligo-dT-coupled  beads  were  first
used  to  enrich  poly-A+RNA  molecules.  First-strand  cDNA
synthesis  was  performed  using  random  hexamers  and
Superscript  II  reverse  transcriptase  (Invitrogen,  USA).
Second-strand  cDNA  synthesis  was  performed  using E.  coli
DNA  PolI  (Invitrogen,  USA).  A  Qiaquick  PCR  purification  kit
(Qiagen, Germantown, MD, Germany) was used to purify the
double-strand  cDNA.  cDNA  was  sheared  with  a  nebulizer
(Invitrogen,  USA) into 100–500 bp fragments.  The fragments
were ligated to a Lumina PE adapter oligo mix after end repair
and  the  addition  of  a  3'  dA  overhang.  The  310–350 bp
fragments  were  then  collected  by  gel  purification.  After  15
cycles  of  PCR  amplification,  the  libraries  were  subjected  to
paired-end  sequencing  using  an  HiSeq2500  (Illumina,  USA)
platform. Finally, 357.58 Gb of transcriptome sequences were
generated from the 91 samples for transcriptome analysis.




vitro  culture  on  glass  cover  slips,  primary  cortical  neurons
were  washed  once  with  Hank's  balanced  saline  solution
(HBSS)  loading  buffer.  We  added  100  μL  of  HBSS  loading
buffer  containing  5  μmol/L  Fluo-3/AM  (Molecular  Probes,
F1241,  USA) dropwise onto the cover  slips,  which were then
incubated with neurons for 45 min at room temperature before
being  washed  twice  with  HBSS  testing  buffer  to  remove
residual fluorescent dye. Neurons were then transferred to the
perfusion  chamber  of  an  OctaFlow  Perfusion  System  (ALA
Scientific  Instruments,  Farmingdale,  NY,  USA),  which  was
placed  on  the  stage  of  a  TCS  SP2  laser  scanning  confocal
microscope  (Leica  Microsystems,  Mannheim,  Germany).
Using  an  excitation  wavelength  of  488  nm  and  emission
wavelength of 526 nm, at least 10 randomly selected neurons
on  every  slide  were  scanned  continuously  at  6  s  intervals  to
determine  real-time  fluorescence  intensity.  Dynamic  changes
in  the  fluorescence  intensity  of  every  neuron  were  recorded
automatically by the Leica confocal system. Changes in [Ca2+]i
(Δ[Ca2+]i)  were  represented  by  changes  in  fluorescence
intensity  before  and  after  drug  administration  and  were
expressed  as:  Δ[Ca2+]i=(F  (peak  fluorescence  intensity  after
administration)   –  F0  (baseline  fluorescence  intensity  before
administration))/F0×100%.
Statistical  analysis  of  behavioral  and  neurological
experiments
Statistical  analyses  were  performed  using  SPSS  19.0  and
graphs  were  drawn  using  GraphPad  Prism  6.0.  Most  data,
including brain water content and number of  injured neurons,
were  analyzed  using  Student's  t-test  or  one-way  analysis  of
variance  (ANOVA)  with  Dunnett's  post-hoc  test  for  multiple
comparisons.  Behavioral  impairment  scores  were  analyzed
using  the  Kruskal-Wallis  test.  All  data  are  represented  as
means±SD unless otherwise noted. P-values of less than 0.05
were considered statistically significant.
Source of genome reference and gene annotation
The  reference  genome  and  gene  annotation  of  the
cynomolgus  monkey  used  in  this  study  were  originally
generated by Yan et al. (2011) and downloaded from GigaDB











Transcriptome  alignment  and  expression  level
measurement
The Hisat2 (v2.0.4) (Kim et al., 2015) package was employed
to  align  transcriptome  reads  to  the  reference  genome  of
cynomolgus  monkey  with  default  parameters.  Gene
expression  was  measured  as  RPKM  (reads  per  kilobase  of
transcript  per  million mapped reads)  using an in-house script
(supplementary  file  "count_reads_num.  pl"),  and  library  sizes
were  normalized  with  the  geometric  method  in  DESeq2
(v1.10.1)  (Love  et  al.,  2014)  (Supplementary  Data).  Genes
expressed  robustly  (i.e.,  mean  RPKM>1)  in  at  least  one
sample  group  were  used  for  principal  component  analysis
(PCA).
Identification of differentially expressed genes (DEGs)
We applied a strict protocol to identify DEGs between groups
of  samples.  Candidate  DEGs  were  first  identified  using
DESeq2  (v1.10.1)  (Love  et  al.,  2014),  edgeR  (v3.12.1)
(Robinson  et  al.,  2010),  and  Cuffdiff  (v2.2.1)  (Trapnell  et  al.,
2013) separately.  For  DESeq2,  the default  method was used
to  normalize  library  sizes,  the  fitting  type  of  dispersions  to
mean intensity was set as "parametric", and the method to test
DEG significance  was  set  as  "nbinomWaldTest".  For  edgeR,
the  trimmed  mean  of  M-values  (TMM)  normalization  method
was  used  to  normalize  library  sizes,  the  quantile-adjusted
conditional  maximum likelihood  (qCML)  method  was  used  to
estimate  dispersions,  and  the  genewise  exact  test
("exactTest") was used to calculate the significance of DEGs.
For Cuffdiff,  the method for library size normalization was set
as  "--geometric-norm"  and  other  parameters  were  set  as
default. P-values were adjusted to allow for multiple testing by
the  Benjamini-Hochberg  False  Discovery  Rate  (FDR)
(Benjamini  & Hochberg,  1995).  A DEG was required to  meet
the  following  criteria:  (1)  at  least  two  of  the  three  DEG-
detection software reported a FDR<0.05; (2) the lower quartile
of expression level in the up-regulated group was greater than
the  upper  quartile  of  expression  level  in  the  down-regulated
group; and, (3) the mean RPKM was not less than 5 in the up-




to  calculate  the  false-positive  rate,  samples  were  randomly
divided into pseudo groups. For WBC samples, three pseudo
groups  were  generated,  each  consisting  of  two  samples
randomly  chosen  from  stage  A,  stage  D,  and  stage  F,
respectively.  For  brain  samples,  two  pseudo  groups  were
generated, each consisting of three samples randomly chosen
from the HH and NN groups, respectively. The procedures for
DEG  detection  described  above  were  performed,  and  the
numbers of DEGs between pseudo groups of the same tissue
were  considered  as  false  positives.  In  contrast  to  the
thousands of significant DEGs identified between real groups,
no  DEGs  were  identified  between  pseudo  groups  for  WBCs
and brain tissue, confirming the robustness of our strategy and
reliability of our results.
Gene ontology annotation,  Kyoto Encyclopedia of  Genes
and  Genomes  (KEGG)  annotation,  and  enrichment
analysis
Gene  ontology  (GO)  terms  (Ashburner  et  al.,  2000)  for  the
cynomolgus  monkeys  were  annotated  according  to  their
orthologous relationships with rhesus macaques and humans
(Supplementary  Table  S5).  KEGG  pathways  (Kanehisa  &
Goto,  2000)  were  annotated  employing  online  KAAS  (KEGG
Automatic  Annotation  Server)  tools  (www.genome.jp/
tools/kaas/)  (Moriya  et  al.,  2007)  using  all  protein  sequences
of  the  cynomolgus  monkeys  as  inputs  with  a  BBH  (bi-
directional best hit) method (Supplementary Table S5).
Fisher's exact tests were employed to identify whether a list
of  genes  (foreground  genes)  was  enriched  in  specific  GO
terms or KEGG pathways, with comparisons of the number of
foreground  genes  annotated  to  the  specific  GO/KEGG,
number  of  foreground  genes  not  annotated  to  the  specific
GO/KEGG,  number  of  background  genes  (excluding
foreground  genes)  annotated  to  the  specific  GO/KEGG,  and
number  of  background  genes  (excluding  foreground  genes)
not  annotated  to  the  specific  GO/KEGG.  P-values  were
adjusted  to  allow  for  multiple  testing  by  means  of  the
Benjamini-Hochberg  False  Discovery  Rate  (Benjamini  &
Hochberg, 1995).
Co-expression module and hub gene identification
The WGCNA (v1.51) (Langfelder & Horvath, 2008) package in
R (v3.2.3) was employed for co-expression network analyses
using  the  percentage  of  transformed  RPKM  of  all  robustly
expressed  genes.  Co-expression  modules  were  identified
using  standard  methods,  with  correlation  between  genes
calculated  by  the  Pearson  method,  and  the  distance  for
hierarchical  clustering  calculated  by  the  Ward  method  (Ward
Jr, 1963). Similar modules were merged by WGCNA with the
parameter  MEDissThres=0.25.  The  eigengene  (vector
presenting  expression  dynamics  of  a  module  between
samples) and kME (correlation of the gene with corresponding
module  eigengene)  in  every  module  were  also  calculated  by
WGCNA.  For  every  module,  genes  with  kME>0.9  were
considered hub genes.
Analysis of impact of drugs on transcriptome dynamics
For WBCs, the sequencing of the HH and drug-treated groups
was  not  performed  in  the  same  batch.  Hence,  laboratory
conditions, personnel differences, and reagent lots could have
caused  variations  between  the  groups,  i.  e.,  batch  effects
(Leek  et  al.,  2010).  It  should  be  noted  that  stage  A  samples
from  the  PROG  and  TRIOL  groups  were  collected  prior  to
drug  injection;  therefore,  the  stage  A  DEGs  between  the  HH
and  drug-treated  groups  were  likely  a  reflection  of  batch
effects  rather  than  drug-specific  effects,  and  were  thus
excluded  from  subsequent  analyses  on  DEGs  between  HH
and drug-treated groups in stages D and F.
For  brains,  we  identified  the  DEGs  between  the  NN,  HH,
and  drug-treated  groups  in  pairwise  comparisons.  Firstly,  we
focused  on  the  impact  of  drug  treatment  on  HH-responding
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genes, which were DEGs between the NN and HH groups. If
an  HH-responding  gene  was  a  DEG  between  the  HH  and
drug-treated groups but not a DEG between the NN and drug-
treated  groups  (i.  e.,  the  expression  level  of  the  gene  in  the
drug-treated  group  was  not  significantly  different  from that  in
the NN group but was significantly different from that in the HH
group),  the  gene  was  considered  to  be  a  drug  strongly
responding  gene  (SRG).  If  an  HH-responding  gene  was  a
DEG between the NN and drug-treated groups but not a DEG
between the HH and drug-treated groups (i.e., the expression
level  of  the  gene  in  the  drug-treated  group  was  not
significantly  different  from  that  in  the  HH  group  but  was
significantly different from that in the NN group), the gene was
considered  to  be  a  drug  non-responding  gene  (NRG).  The
other  HH-responding  genes  with  expression  levels  that  fell
between  the  drug-treated,  NN,  and  HH  groups  were
considered drug weakly responding genes (WRGs). If a gene
was not significantly differentially expressed by HH in contrast
to  NN (i.e.,  not  a  DEG between  the  HH and  NN groups)  but
was  significantly  differentially  regulated  by  a  drug  in  contrast
to both NN and HH conditions, it was considered to be a drug-
induced  DEG.  Even  if  a  gene  was  significantly  up-  or  down-
regulated  by  HH,  if  that  gene  was  further  significantly  up-  or
down-regulated  but  not  restored  by  the  drug,  it  was  also
considered to be a drug-induced DEG, not an NRG.
RESULTS
Monkeys  develop  severe  brain  injuries  under  acute  HH
conditions  that  can  be  significantly  alleviated  by  PROG
and TRIOL
Twenty-four  healthy,  adult  male  cynomolgus  monkeys  were
classified  into  four  groups  (n=6):  i.  e.,  normobaric  normoxia





velocity  of  2–3 m/s  (HH  group).  Altitude  simulation  for  each
monkey started at 320 m (stage A) and was then sequentially
suspended  at  3  000  m  (stage  B),  4  500  m  (stage  C),  and








The  impact  of  acute  HH  exposure  on  behavior  was
assessed 2 h after ascending to 7 500 m. In sharp contrast to
the  NN  monkeys,  which  exhibited  high  activity  levels  with
frequent  walking,  climbing,  and  eating,  the  HH  monkeys  lost
their  balance and lay prostrate with limited body movements,
or  even  remained  in  lateral  or  dorsal  recumbency  during  the
entire  behavioral  assessment.  All  six  monkeys  in  the  HH
group displayed anorexia, vomiting, motor deficits, and ataxia.
In  contrast,  monkeys  in  the  HH+PROG  and  HH+TRIOL
groups were able to maintain their balance and remain seated,
with  frequent  head  and  forelimb  movements.  Several  PROG
or  TRIOL-treated  animals  exhibited  normal  feeding  behavior
or short-distance movements (a few steps), although vomiting
still  occurred  in  some monkeys  (two  PROG-treated  monkeys
and  four  TRIOL-treated  monkeys).  We  then  employed
behavioral  deficit  scoring  to  obtain  a  quantitative  measure  of
skeletal  muscle  coordination  by  recording  the  movements  of
each monkey over 30 min (Supplementary Table S1) (Kito et






1D),  indicating  that  PROG  and  TRIOL  were  able  to  partially
restore motor coordination in HH monkeys.
Cerebral  edema  is  normally  manifested  as  the  increase  of
the  water  content  in  the  brain  tissue.  We  found  that  brain
water  content  was  significantly  higher  in  the  HH  group
(76.71%±0.30%)  than  in  the  NN  group  (76.16%±0.26%)
(ANOVA  P<0.01,  Figure  1E).  The  proportion  of  brain  water
content  was significantly  reduced in  both the HH+PROG and
HH+TRIOL  groups  to  76.12%±0.46%  and  76.28%±0.23%,
respectively,  similar  to  levels  in  the  NN  group  (Figure  1E).
Additionally,  the  pericapillary  space  was  markedly  wider  in
untreated  HH  brains  than  in  other  groups  (Figure  1F),
suggesting  that  blood-brain  barrier  (BBB)  disruption  and
vasogenic  edema,  which  are  considered  to  cause  cerebral
edema in patients with HACE (Bärtsch & Swenson, 2013), had
been  induced  by  HH  and  reversed  by  drug  administration.
Nissl  staining  of  the  frontal  cortex  revealed  many  injured
neurons in the HH group only. These cells were characterized
by  dark  staining,  condensed  nuclei,  shrunken  cell  bodies,  or
weak  staining  with  irregular  shapes  (Figure  1G).  The
proportion  of  injured  neurons  in  the  HH  group  was  21.1%,
significantly higher than that in the NN group (1.4%) (ANOVA
P<10–3).  This  ratio  was  restored  to  7.5%  in  the  HH+PROG
group  (ANOVA  P<0.01)  and  6.7%  in  the  HH+TRIOL  group
(ANOVA P<0.01, Figure 1H; see Methods).
Taken  together,  these  findings  suggest  that  cynomolgus
monkeys  develop  severe  motor  impairments  and  brain
damage  after  acute  exposure  to  HH  environments,  and  this
can be significantly mitigated by either PROG or TRIOL.
WBC dynamic transcriptome analysis reveals three major
regulatory modules responding to acute HH
To  systematically  investigate  the  genetic  regulatory  networks
that  participate  in  the  HH  response,  we  sequenced  and
analyzed the transcriptome of  WBCs obtained at  each of  the
six HH stages, A–F (n=6, 36 WBC samples in total). Based on
PCA of  12  198  robustly  expressed  genes,  the  degree  of  HH
exposure  (i.  e.,  a  function  of  altitude  plus  exposure  time),
rather  than  individual  differences,  appeared  to  be  the  main
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 Figure 1  Acute HH-induced behavioral and cerebral impairments were attenuated by PROG and TRIOL treatments




factor  affecting  the  genome-wide  WBC  gene  expression
patterns  (Figure  2A).  We  then  identified  DEGs  based  on
comparisons  between  any  two  of  the  six  HH  stages  (see
Methods)  and  obtained  a  total  of  5  174  DEGs  across  all
comparisons (ranging from 0–3 864 for different comparisons).
As  stage  A  (simulated  altitude  of  320  m)  represents  the  NN
condition, the number of DEGs between this and other stages
reflects the degree of gene expression change in response to
varying  levels  of  HH  exposure.  The  number  of  DEGs
increased  incrementally  from  stages  B  to  D,  reaching  its
highest  at  stage  D.  During  stages  E  and  F,  the  number
decreased  (Figure  2B),  implying  that  the  increased  gene
expression changes associated with HH were reversed in later
stages,  probably  because  of  organismal  acclimatization  to
hypoxia after 24 h of exposure to HH (Berglund, 1992).
Co-expression  analysis  was  next  used  to  identify  co-
expression  modules  associated  with  HH  changes  (see
Methods). Eight modules were identified, ranging in size from
64  to  5  607  genes  (Supplementary  Figure  S1A,  B).  Three
modules were significantly enriched with DEGs (Fisher's exact
test  P<10–15)  and  showed  strong  correlation  between  the
expression  pattern  and  progression  of  HH  (ANOVA P<10–4;
Supplementary Table S2). Hence, these were considered the
primary  HH-responding  modules  (HH  modules).  The  first  HH
module  contained  3  114  genes,  2  123  (68%)  of  which  were
DEGs  (Supplementary  Table  S2).  This  module  (termed  the
'impulse  module')  showed  an  'impulse  pattern',  whereby  the
expression levels were monotonically increased or decreased
in  the  early  stages  of  HH  (stages  A–D),  but  recovered  to  a
certain  extent  during  the  later  stages  (stages  E–F)  (Figure
2C).  The  second  HH-responding  module  (termed  the
'sustained module') contained 571 genes, 479 (84%) of which
were  DEGs  (Supplementary  Table  S2).  In  this  module,
changes  in  expression  levels  of  genes  that  responded  to
early-stage  changes  in  altitude  were  sustained  in  the  later
stages of HH (Figure 2C). The third module (termed the 'late-
responding  module')  contained  552  genes,  398  (72%)  of
which  were  DEGs  (Supplementary  Table  S2).  Genes  in  this
module showed no differential expression until the later stages
of HH (Figure 2C).
Impulse  responses  of  hypoxia/HIF-1  mediated  innate
immunity and inflammatory processes to acute HH
Genes  in  the  impulse  module  were  significantly  implicated  in
several  classical  pathways  critical  to  hypoxia  response  and
inflammation (Figure 2D–E, and Supplementary Figure S1C).
As  noted  in  previous  small  mammal  and  human  cell  line
studies,  we  confirmed  that  the  HIF-1  signaling  pathway  also
played  a  regulatory  role  in  adaptive  responses  promoting
optimal  oxygen  utilization  (Semenza,  2009)  and  in
inflammatory responses (Palazon et al., 2014) to hypoxia in in
vivo  primate  experiments.  Other  innate  immune  and
inflammatory pathways such as the NF-κB,  Toll-like receptor,
and  FoxO  signaling  pathways,  were  also  activated,  probably
forming a positive feedback loop with HIF-1 (Han et al., 2016).
The  inflammatory  factor  IL1B  and  chemokine CXCL1,  which
constitute links with HIF-1 and NF-κB signaling (Hatfield et al.,
2010;  Jung  et  al.,  2003),  were  up-regulated  by  HH  in  the
impulse  module  and  are  known  to  contribute  to  vascular
impairment  and  vasogenic  edema  (Stamatovic  et  al.,  2006),
as observed in the brains of the HH-treated group (Figure 1F).
Collectively,  HIF-1/hypoxia  pathways  mediating  the
inflammatory  response  may  contribute  to  pathogenesis  in





were  consistently  down-regulated  by  HH,  suggesting  overall
suppression  of  the  adaptive  immune  system  in  the  HH
environment.
Emergence of RBC-associated inflammatory processes in
late stages
The late-responding module mainly contained genes involved
in  erythropoiesis  and  platelet  activation  (Figure  2D  and
Supplementary  Figure  S1C).  Several  genes  encoding  key
 


































factors  in  erythropoiesis,  including  erythroid  transcription
factors  (e.g.,  GATA1  and  KLF1),  erythropoietin  receptor
EPOR,  alpha and beta-globin genes (e.g., HBA1, HBA2,  and
HBB), hemoglobin stabilizing protein AHSP, key synthases of
heme  (e.g.,  HMBS,  ALAD,  and  UROS),  tropomodulin-1
TMOD1,  and  E3  ubiquitin-protein  ligase  TRIM58,  were
significantly  up-regulated  during  stages  E  and  F
(Supplementary  Figure  S1D).  This  suggests  that  the
enhanced expression of erythropoiesis genes was induced as
an adaptive response after 28–52 h (stages E–F, Figure 1A)
of  HH  exposure,  which  can  regulate  erythropoiesis  and
improve  oxygen  supply,  thereby  attenuating  the  impact  of
hypoxia  in  later  stages.  Key  genes  of  blood  coagulation  and
inflammation  were  also  significantly  up-regulated  in  late
stages,  including  GP1BA,  F2R,  and  other  important
procoagulant/antifibrinolytic  factors  (e.g.,  VWF,  SERPINE1,
and F13A1) that are associated with impairments of RBCs and
vascular inflammation (Bergmeier et al., 2006; Gemmati et al.,
2016;  Sparkenbaugh  &  Pawlinski,  2013).  In  addition,  the
expression of the haptoglobin gene HP, a major scavenger of
free  hemoglobin,  was  also  significantly  up-regulated  by  HH
(Supplementary  Figure  S1D),  reflecting  a  homeostatic
response  to  the  increased  release  of  free  hemoglobin  from
impaired RBCs.
Intriguingly,  in  the  late-responding  module,  we  also  found
genes  encoding  critical  markers  of  neutrophil  degranulation,
including  neutrophil  elastase  (ELANE),  myeloperoxidase
(MPO),  and  cathepsin  G  (CTSG),  the  expression  levels  of
which were up-regulated by HH (Supplementary Figure S1D).
These  activated  neutrophils  are  tightly  connected  with  BBB
disruption,  vascular  inflammation,  and  vasogenic  edema  in
injured  brains  (Ikegame  et  al.,  2010;  Liu  et  al.,  2018),  which
could  contribute  to  the  development  of  the  HACE-like
symptoms observed in monkeys.
Vitamin  D  receptor  (VDR)  signaling  is  a  novel  key
regulator involved in HH response
We  next  searched  for  intra-modular  hub  genes  (i.  e.,  genes
with the highest degree of connectivity with other genes in the
same module) in the three HH-responding modules to identify
core  regulators  of  the  regulatory  networks  (see  Methods).  A
total  of  326 hub genes  were  identified  (Supplementary  Table
S3),  including  those  encoding  key  transcription  factors,
kinases,  and  receptors  from  the  HIF-1  and  FoxO  signaling
pathways  (e.g.,  STAT3,  FOXO4,  and  PTEN  in  the  impulse
module), T cell receptor signaling (e.g., LCK and PTPN4 in the
sustained  module),  and  erythrocyte  development  and
maintenance  (e.g.,  TMOD1,  TRIM58,  and  KLF1  in  the  late-
responding module).
Interestingly,  our  hub  gene  analysis  also  identified  the
vitamin  D  receptor  (VDR)  signaling  pathway  as  an  important
but  previously  unreported  pathway  involved  in  the  HH
response.  Specifically,  genes  encoding  two  key  transcription
factors, VDR  and  retinoid  X  receptor  alpha  (RXRA),  and  two
co-activators,  nuclear  receptor  coactivator  1  (NCOA1)  and
tripartite motif containing 24 (TRIM24), were identified as hub
genes  in  the  impulse  module  and  were  up-regulated  at  an
early stage (Figure 2F). VDR and RXRA encode proteins that
together  form  a  heterodimeric  complex  that  serves  as  a
nuclear receptor for calcitriol, the hormonally active metabolite
of vitamin D (Kato, 2000). Previous studies have revealed that
VDR can inhibit  the transcriptional  activity  of  NF-κB (Chen et
al., 2013b) and HIF-1 (Chung et al., 2009). VDR may also be
up-regulated  by  Toll-like  receptors  and  participate  in  the
regulation  of  both  the  innate  and  adaptive  immune  systems
(Adams  &  Hewison,  2008).  These  observations  raise  the
possibility  that  the  VDR  pathway  may  function  as  a  hub
regulatory  network  that  balances  HIF-1  signaling  and  its
inflammatory  responses.  Consistent  with  this,  the  vitamin  D-
binding  protein  in  humans  is  associated  with  HH  adaption  in
high-altitude  dwelling  native  peoples  (Ahmad  et  al.,  2013),
whereas VDR in mouse endothelial cells protects brains from
hypoxia/reoxygenation-induced  BBB  disruption  (Won  et  al.,
2015).
Diverse effects of PROG and TRIOL on HH-induced WBC
transcriptome dynamics
To evaluate  the effects  of  two neuroprotective  steroid  agents
on  the  blood  cell  transcriptome,  we  collected  WBC  samples
for  RNA-seq  analysis  from  the  HH+PROG  and  HH+TRIOL
groups  at  stages  D  and  F  (Figure  1B),  because  stage  D
exhibited  the  most  dynamic  response  to  HH (Figure  2B)  and




significant  impact  on their  WBC transcriptome dynamics,  and
the  degree  of  HH  exposure  remained  the  primary
differentiating factor between samples (Figure 3A).
To  further  quantify  the  potential  effects  of  the  two
neuroprotective  agents  on  specific  genes  and  pathways,  we
identified  agent-induced  DEGs  by  comparing  the  gene
expression  between  samples  from  agent-treated  (HH+PROG
or  HH+TRIOL)  and  untreated  HH groups  at  stages  D  and  F.
We  identified  134  DEGs  induced  by  PROG  in  stages  D  (70
DEGs)  and  F  (72  DEGs)  and  found  that  these  DEGs
overlapped  significantly  with  those  from  the  late-responding
module  (Figure  3B  and  Supplementary  Figure  S2A,  Fisher's
exact  test: P<10-12).  In  particular,  key  erythrocyte-associated




FC=3.40,  FDR=0.000 1),  heme  synthases  (SLC25A39:
FC=2.10, FDR=0.008 3; ALAS2: FC=3.43, FDR=0.000 3), and
bisphosphoglycerate mutase (BPGM: FC=2.33, FDR=0.026 6)
(Figure  3C).  Thus,  although  PROG  appeared  to  have  a
relatively  subtle  effect  on  the  WBC  transcriptomes,  we
speculate that this steroid may function specifically to enhance
erythropoiesis  and  elevate  oxygen  transport  in  the  blood,
thereby  helping  to  relieve  the  symptoms  caused  by  HH
exposure.
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Compared  with  PROG,  TRIOL  had  significantly  broader
effects on the WBC transcriptome (Figure 3B), inducing 1 676
DEGs  during  stages  D  (195  DEGs)  and  F  (1 605 DEGs).
Interestingly,  these  TRIOL-induced  DEGs  overlapped
significantly with HH-induced DEGs in all three HH-responding
modules  (Supplementary  Figure  S2A).  Functional  enrichment
analysis  revealed  that  TRIOL  significantly  up-regulated
HIF1/hypoxia  and  RBC-associated  inflammation,  and  down-
regulated T cell  receptor  signaling during stage F (Figure 3D
and Supplementary Figure S2B).  Thus,  in  contrast  to  PROG,
which  had  a  specific  function  in  erythropoiesis,  TRIOL
treatment altered the expression of a broader variety of genes
in WBCs in terms of HH-related functions.
Profound transcriptomic alterations underlie pathological
effects of HH-induced brain injuries
To  investigate  the  brain  gene  regulatory  network  underlying
the acute HH response, and the effects of PROG and TRIOL,
we  performed  RNA-seq  on  frontal  cortex  samples  (brains)
from all monkeys after HH treatment (Figure 1A, B). Based on






treatment  (Figure  4A).  Moreover,  both  agent-treated  groups
clustered tightly together, but separately from the HH group at
the PC2 level (34.8% of total variance) and from the NN group
at  the  PC3  level  (23.8%  of  total  variance)  (Figure  4A),




Figure 3  Regulation of WBC transcriptomic dynamics by PROG and TRIOL
A: Principal component analysis (PCA) using genes robustly expressed in at least one of nine sample groups (i.e., no-drug treated group, PROG-




specific  effects.  C:  Erythrocyte-associated  DEGs  up-regulated  by  PROG.  Red  color  and  arrows  denote  genes  up-regulated  by  PROG.  D:








 Figure 4  Transcriptomic changes in frontal cortex in response to acute HH, PROG, and TRIOL
A: Principal component analysis (PCA) using genes robustly expressed in at least one of four sample groups (normobaric normoxia [NN], HH, HH+
PROG, and HH+TRIOL). Colors denote sample group. B: Expression changes of HH-induced differentially expressed genes (DEGs) after PROG or
TRIOL treatment,  shown as  log2-transformed  reads  per  kilobase  of  transcript  per  million  mapped  reads  (RPKM)  fold  changes  of  DEGs in  each
sample  group  compared  to  NN  group.  HH-induced  DEGs  are  categorized  into  strongly  responsive  genes  (SRGs),  weakly  responsive  genes
(WRGs), and non-responsive genes (NRGs) according to their degree of expression level recovery after drug treatment. Red and light blue lines
denote expression patterns of individual DEGs up- and down-regulated by HH, respectively. Bold lines show mean expression levels of all HH up-
or  down-regulated  DEGs  in  each  group,  with  error  bars  representing SD.  Percentages  of  SRGs  and  WRGs  versus  all  HH-induced  DEGs  are
presented above each plot. C: Expression changes of drug DEGs after PROG or TRIOL treatment, shown as log2-transformed RPKM fold changes
of  DEGs  in  each  sample  group  compared  to  NN  group.  Red  and  light  blue  lines  denote  expression  patterns  of  individual  DEGs  up-  or  down-
regulated by drugs, respectively. Bold lines show mean expression levels of all DEGs up- or down-regulated by drugs in each group, with error bars
representing  SD.  D:  Kyoto  Encyclopedia  of  Genes  and  Genomes  (KEGG)  pathways  enriched  in  HH-induced  or  drug-recovered  DEGs.  Only
significantly enriched pathways with a false discovery rate (FDR)-adjusted P-value of <0.05 are plotted. In HH DEGs, SRGs, WRGs, and NRGs, red
and blue dots denote pathways enriched in DEGs up- and down-regulated by HH, respectively. In drug DEGs (PROG DEGs and TRIOL DEGs), red








(see  Methods),  with  1 446  up-regulated  and  1 546  down-
regulated  by  HH  (Supplementary  Table  S4),  reflecting
considerable  regulatory  and  functional  rewiring  in
brainexpressed  genes  in  response  to  acute  HH  exposure.
DEGs showing the largest expression fold changes (top 1% of
all  DEGs)  comprised  the  hemoglobins  (carrier  of  oxygen)
HBA1  (FC=10.69,  FDR=0.000 0)  and  HBA2  (FC=4.12,
FDR=0.000 2),  and  several  angiogenesis-related  genes,
including  adrenomedullin  ADM  (FC=13.58,  FDR=0.000  0),
vascular  endothelial  growth  factor  VEGFA  (FC=5.48,
FDR=0.000 0),  and  apelin  APLN  (FC=3.29,  FDR=0.000 0),
which  were  all  up-regulated  in  HH  brains.  It  is  worth  noting
that many tightly associated DEGs were also significantly up-
regulated  by  HH,  including  VEGFB  (F=1.58,  FDR=0.000  0),
receptor of vascular endothelial growth factor FLT1 (FC=2.62,
FDR=0.000  0),  and  receptor  of  adrenomedullin  RAMP2
(FC=1.45,  FDR=0.006 2).  This  strongly  suggests  that  an
adaptive  response  to  HH,  by  increasing  local  tissue
oxygenation  and  increasing  oxygen  delivery,  occurred  in
monkey  brains  after  52  h  of  HH  exposure.  However,  VEGF
expression  can  also  promote  BBB  leakage  (Schoch  et  al.,
2002), as observed in all monkeys exposed to HH (Figure 1F).
Of  note,  CARTPT,  a  gene  that  encodes  neuropeptides
controlling  feeding  (Lambert  et  al.,  1998),  locomotor  activity
(Kimmel  et  al.,  2002),  and  stress  response  (Rogge  et  al.,
2008),  also emerged as a top DEG (FC=6.88, FDR=0.000 3)
between  NN  and  HH  groups,  and  its  up-regulation  in  HH
brains  likely  played  a  role  in  inducing  the  symptoms  of
anorexia and motor deficits in HH monkeys.
As with WBC transcriptome analysis,  functional enrichment
analyses  revealed  that  HIF-1  signaling  was  significantly
enriched  by  DEGs  up-regulated  in  HH  brains  (Figure  4D),
including  EPAS1  (FC=1.37,  FDR=0.028 5)  and  EGLN1
(FC=1.48, FDR=0.004 7),  two  genes  strongly  associated  with
high-altitude adaptation in highland populations (Simonson et
al., 2010; Yi et al., 2010), and HIF3A (FC=4.36, FDR=0.000 0),
an  important  regulator  of  HIF1A  and  EPAS1  involved  in
adaptive  responses  to  hypoxia  (Ravenna  et  al.,  2015).
Moreover, given that the top DEGs (e.g., ADM, VEGF, APLN,
HBA1,  and HBA2)  are  regulated by HIF-1 signaling (Chen et
al., 2012; Eyries et al., 2008; Ramakrishnan et al., 2014; Saha
et  al.,  2014),  this  suggests  that  HIF-1  signaling  also  plays  a
main  regulatory  role  in  adaptive  responses  to  acute  HH  in
brains.  Additionally,  genes  involved  in  the  complement  and
coagulation  cascades,  and  in  leukocyte  transendothelial
migration, were up-regulated in HH-exposed brains (Figure 4D
and  Supplementary  Figure  S3A)  and  WBCs  (Figure  2D),
implying  a  link  between  peripheral  inflammation  and
neuroinflammation in the CNS.
As a consequence of the decrease in oxygen supply under
HH  conditions,  several  pathways  involved  in  aerobic
respiration  were  found  to  be  down-regulated  in  HH  brains,
including  oxidative  phosphorylation,  respiratory  electron
transport  chain,  tricarboxylic  acid  (TCA)  cycle,  and  pyruvate
metabolism.  On  the  other  hand,  pathways  involved  in
anaerobic  respiration  were  up-regulated,  including  glycolysis
and  mTOR  signaling  (Figure  4D  and  Supplementary  Figure
S3A). These findings suggest that, regardless of the adaptive
response by  stimulating  angiogenesis  and  increasing  oxygen
delivery,  the  monkey  brains  suffered  an  energy  deficiency,
which  may  have  induced  autophagy  and  neuronal  injuries
through mTOR signaling (Dunlop & Tee, 2014).
Protein  misfolding  and  endoplasmic  reticulum  (ER)  stress
are  involved  in  many  types  of  brain  injury  and
neurodegenerative  diseases  (Giffard  et  al.,  2004;  Soto  &
Estrada,  2008).  Indeed,  we  found  that  many  key  genes
involved in the protein folding process were down-regulated by
HH  (Supplementary  Figure  S3A),  including  those  encoding
members of the HSP40 family, prefoldins, and FK506 binding
proteins  (Supplementary  Table  S4).  Members  of  the  HSP40
family  are crucial  partners for  HSP70 chaperones (Qiu et  al.,
2006),  and  are  important  for  hypoxic  tolerance  (Jain  et  al.,
2014)  and  injury  resistance  (Hasegawa  et  al.,  2018)  in  the
CNS.  Thus,  their  down-regulation  may  exacerbate  HH-
induced brain injury.
Taken together,  our  results  revealed  profound neural  gene
expression  alterations  after  exposure  to  acute  HH,  and
rewiring  of  genetic  pathways,  which  may  contribute  to  an
adaptive response to  acute HH and underlie  the pathological
effects of the associated brain injuries.
Brain transcriptomic changes induced by HH are reversed
by treatment with PROG and TRIOL
We  then  assessed  how  PROG  and  TRIOL  affect  the
expression  of  HH-altered  genes  (see  Methods).  Of  all  HH-
altered genes,  the expression levels  were restored to  normal
(defined by reference to the NN group) in 50.67% and 48.09%
of  cases  by  PROG  and  TRIOL  treatment,  respectively,  i.  e.,
'strongly responsive genes' (SRGs) (Figure 4B). Furthermore,
31.52%  and  29.45%  of  HH-altered  genes  were  partially
restored  by  PROG  and  TRIOL  treatment,  respectively,  i.  e.,
'weakly  responsive  genes'  (WRGs)  (Figure  4B).  In  addition,
the  expression  levels  of  17.15%  and  20.82%  of  HH-altered
genes  were  unaffected  by  PROG  and  TRIOL  treatment,
respectively, i.e.,  'non-responsive genes' (NRGs) (Figure 4B).






similar  effects  on  reversing  HH-induced  transcriptomic
changes in the brain.
PROG  and  TRIOL  SRGs  were  particularly  enriched  in
components of the key pathways of aerobic respiration (Figure
4D  and  Supplementary  Figure  S3A),  suggesting  an
improvement  in  aerobic  energy  supply  in  response  to  PROG
and TRIOL treatment. Specifically, of the 44 genes involved in
oxidative  phosphorylation  and  down-regulated  by  HH,  25




than  PROG.  The  abnormal  HH-induced  expression  of  genes
with roles in protein folding was also restored by both PROG
and  TRIOL  treatment  (Figure  4D  and  Supplementary  Figure
S3A),  which may relieve neuronal  injuries  induced by protein
folding  and  ER  stress.  In  addition,  the  up-regulation  of  the
behavior-related gene CARTPT by HH was also attenuated by





including  ADM,  VWF,  and  VEGFA,  suggesting  that
angiogenesis  was  also  active  in  drug-treated  groups
(Supplementary Table S4). Intriguingly, PROG but not TRIOL
further  up-regulated  several  key  genes  involved  in
angiogenesis  and  oxygen delivery,  including VEGFA  (HH-vs-
PROG:  FC=1.23,  FDR=0.032  3),  its  receptor  FLT1  (HH-vs-
PROG: FC=1.23, FDR=0.032 3), and hemoglobins HBB (HH-
vs-PROG: FC=2.33, FDR=0.002 4) and HBA2 (HH-vs-PROG:
FC=1.97,  FDR=0.000  0)  (Supplementary  Table  S4).  These
results  further  emphasize  the  potential  role  of  PROG  in
relieving HH-induced symptoms by elevating oxygen transport
in both WBCs and brains.
Gene regulatory mechanisms by which TRIOL suppresses
glutamate-mediated excitotoxicity
In the brain transcriptome, we detected many genes that were
specifically  rewired  by  either  PROG  or  TRIOL,  even  though
their expression levels were not altered by HH treatment (see
Methods,  Figure  4C).  These  included  380  and  743  genes
whose expression levels were induced by PROG and TRIOL,
respectively.  Intriguingly,  among them,  we found that  TRIOL,
but  not  PROG,  significantly  induced the  enrichment  of  DEGs
in  many  key  excitatory  neuronal  signaling  pathways  (Figure
4D  and  Supplementary  Figure  S3A),  including  the
glutamatergic  synapse,  L-glutamate  import,  glutamate
receptor,  and calcium signaling pathways.  This suggests that
TRIOL  may  have  a  specific  effect  on  the  regulation  of
glutamate-induced  excitotoxicity.  Glutamate  induces
excitotoxicity by promoting the excessive influx of intracellular
calcium  [Ca2+]  through  ionotropic  glutamate  receptors,
particularly  through  the  N-methyl-d-aspartate  (NMDA)
receptor. This is the main cause of hypoxia-induced neuronal
death  in  many  hypoxia-induced  brain  injuries  (Wroge  et  al.,
2012).  Many  key  genes  involved  in  this  process  were  down-
regulated  by  TRIOL,  including  NMDA  receptors  GRIN2A
(FC=1.79, FDR=0.000 0) and GRIN2B (FC=2.23, FDR=0.000 3),
vesicular glutamate transporter (VGLUT) SLC17A7 (FC=1.63,
FDR=0.000 0),  excitatory  amino  acid  transporter  (EAAT)
SLC1A2  (FC=1.60,  FDR=0.018 4),  group  I  metabotropic
glutamate  receptor  GRM5  (FC=1.48,  FDR=0.030 4),  and  its
downstream  adenylate  cyclase  family  members  ADCY1
(FC=1.52,  FDR=0.029 1),  ADCY3  (FC=1.39,  FDR 0.009 8),
ADCY5  (FC=1.55,  FDR 0.003 8),  and  ADCY9  (FC=1.59,
FDR=0.000 2) (Figure 4E and Supplementary Table S4).
Glutamate-induced intracellular calcium ([Ca2+]i) overload is
part  of  the  signature  indicating  excitotoxicity  in  neurons
(Scannevin  &  Huganir,  2000).  To  further  examine  whether
TRIOL  can  indeed  reduce  neuronal  excitotoxicity  by  directly
suppressing  the  intracellular  accumulation  of  calcium,  we
measured  glutamate-induced  [Ca2+]i  in  primary  rat  cortical
neurons with and without TRIOL treatment. We observed that
stimulation  with  100  μmol/L  glutamate  alone  dramatically
increased  [Ca2+]i  in  neurons  within  50 s,  whereas
supplementation  with  TRIOL  decreased  these  glutamate-
induced  effects  in  a  dose-dependent  fashion  (Figure  4F).
Taken together, our results suggest that TRIOL may suppress




In  this  study,  we  demonstrated  that  cynomolgus  monkeys
exposed  to  acute  HH  exhibited  various  symptoms,  including
anorexia,  vomiting,  motor  deficits,  and ataxia,  as observed in
human  patients  suffering  acute  high-altitude  diseases  and
which  are  mostly  attributed  to  pathological  changes  in  the
brain (Wilson et al.,  2009).  The pathophysiological  diagnoses
in  the  brain  suggest  that  cynomolgus  monkeys  developed
severe cerebral edema, similar to that found in human HACE
patients (Hackett & Roach, 2004). Hence, these data suggest
cynomolgus  monkeys  can  be  used  as  non-human  primate
models  for  studying  the  disorders  of  oxygen  homeostasis.
Moreover, the genetic regulatory networks shown in this study
to  be  involved  in  the  development  of  hypoxia-induced  brain
malfunctions  provide  valuable  insights  into  the  relationship
between  the  mechanism  of  oxygen  homeostasis  regulation
and  related  diseases.  Our  study  confirmed  the  fundamental
role of several classical pathways, such as HIF-1 signaling, in
the  organism  level  response  to  hypoxia.  Moreover,  we  also
revealed  that  several  molecules,  such  as  VDR,  serve  as
central  connectors  of  different  acute  HH response  pathways;
these  have  been  largely  ignored  in  previous  studies  using
human cell lines or mice as experimental models.
The  dynamic  transcriptome  of  WBCs  from  non-human
primates  may  help  to  improve  our  understanding  of  the
progression  of  HACE.  First  of  all,  most  genes  were
categorized  as  belonging  to  the  impulse  module,  including
those  involved  in  HIF-1  signaling;  the  expression  of  these
genes was stimulated during early HH stages but recovered in
late  stages,  suggesting  that  hypoxia  is  indeed  the  primary
cause of injury under acute HH conditions. The hub genes in
the  impulse  module  may  account  for  the  subsequent
expression  changes  in  genes  in  the  late  stages  of  HH  and
may  be  responsible  for  the  fundamental  pathophysiological
changes  involved  in  acclimatization  or  injury.  For  example,
RBC-associated  inflammation  is  a  novel  pathway  in  late
stages  and  may  interact  with  the  progress  of  HACE.  Our
transcriptomic  analyses  combining  WBCs  and  brains  also
highlighted a complex organismal response to acute HH, with
active  crosstalk  between  the  acclimatization  that  maintains
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oxygen  homeostasis  and  adverse  pathological  feedback
caused  by  inflammation.  Specifically,  in  addition  to  the
activation  of  the  HIF-1  signaling  pathway,  consistent  with
previous  reports  (Semenza,  2009;  Wilson  et  al.,  2009),  we
also  found  that  HH may  induce  a  hierarchy  of  transcriptional
programs  of  both  innate  and  adaptive  immunity,  while
progressively  promoting  inflammation  in  both  the  blood  and
brain.
The  development  of  treatments  for  brain  injury  associated
with HH, such as HACE, remains a formidable challenge. Our
pharmacogenomic  studies  reported  here  provide  preliminary
but  nevertheless  valuable  insights  into  the  feasibility  of  a
generalized  neuroprotection  strategy.  Further,  they  present
possible  drug  candidates,  PROG  and  TRIOL,  which  both
alleviated  acute  HH-induced  brain  injuries  in  our  primate
model. PROG is reported to be neuroprotective by stimulating
breathing,  increasing  oxygen-carrying  capacity,  and
modulating  the  GABAa  receptor  to  suppress  excitotoxicity
(Singh  &  Su,  2013),  whereas  our  results  suggested  a  role  in
stimulating  erythropoiesis  and  increasing  oxygen  delivery.
Medroxyprogesterone  (MPA),  a  synthetic  analogue  of  PROG
without neuroprotectant properties (Singh & Su, 2013), is used
to  treat  chronic  mountain  sickness  by  stimulating  breathing
and  increasing  blood  oxygen  levels  (Wright  et  al.,  2004).
However, MPA has no significant prophylactic effect for acute
mountain  sickness  (AMS)  (Wright  et  al.,  2004),  which  further
emphasizes  the  importance  of  neuroprotection  in  treating
HACE.  It  is  intriguing  that  the  two  neuroprotectants,  PROG
and TRIOL, appear to have different modes of action and act
through  distinct  functional  mechanisms  to  rewire  the
expression  of  genes  in  the  blood  and  brain.  Our  previous
study  reported  that  TRIOL  can  protect  primary  cortical
neurons  from  hypoxia/reoxygenation  injury  by  maintaining
mitochondrial functions (Chen et al., 2013a). Here, we further
revealed  that  the  neuroprotective  effect  of  TRIOL  may  be
mediated by attenuation of glutamate-induced excitotoxicity.
In  conclusion,  our  research  extends  the  transcriptomic
analysis  of  acute  HH  responses  at  an  integrated  spatial  and
temporal level in non-human primates. We presented a kinetic
transcriptomic analysis of WBCs and the transcriptomic profile
of  brains  after  exposure  to  acute  HH.  Our  data  revealed
thousands of genes regulated by acute HH and categorized to
different  co-expression  modules  depending  on  their  spatial
and  temporal  dimensions.  Our  study  also  revealed  that
neuroprotective  steroids  such  as  PROG  and  TRIOL  have
significant  recovery  effects  on  acute  HH-induced  behavioral
deficits  and  brain  damage,  suggesting  the  potential  of  using
novel  neuroprotectants  as  therapeutic  drugs  for  acute  high-
altitude  diseases.  However,  we  also  acknowledge  that  there
are  ~25  million  years  of  evolutionary  divergence  between
cynomolgus  monkeys  and  humans  (Yan  et  al.,  2011),  and
some  routine  physiological  data  such  as  arterial  blood
pressure,  arterial  oxygenation,  and  ventilation  were  not
collected  in  this  study  due  to  the  limitation  of  experimental
conditions. Thus, we cannot rule out that the pathological and
gene  regulatory  changes  observed  in  the  cynomolgus
monkeys may differ from that in humans suffering HH-induced
disorders.  Future  studies  with  relevant  physiological




The  underlying  sequence  data  used  in  this  study  were
deposited  with  the  National  Center  for  Biotechnology
Information (NCBI) under accession No. PRJNA431946 and in
the  CNSA  (https://db.cngb.org/cnsa/)  of  CNGBdb  with
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